摘要
目的:分析微柱凝胶免疫方法检测患者血清中抗肿瘤药物类抗体水平的临床价值。方法:选取2018年1月-2020年1月80例肿瘤患者的血清标本,其中37例服用曲妥珠单抗抗体,余下43例服用卡培他滨抗体。分析患者血清中抗肿瘤药物类抗体水平。结果:80例患者的血清标本检查之后,有5例患者的血清中存在抗体,检出率为6.25%,其中1例患者的血清中存在曲妥珠单抗抗体,4例患者的血清中存在卡培他滨抗体,曲妥珠单抗抗体的检出率为2.70%,而卡培他滨的检出率为9.30%,曲妥珠单抗抗体的检出率低于卡培他滨的检出率。结论:肿瘤疾病患者,需要长时间服用抗肿瘤药物,患者的体内有可能出现抗肿瘤药物类的抗体,从而使抗肿瘤药物的效果大大降低,出现多种免疫性不良反应,所以,降低患者体内的抗肿瘤药物的抗体生成率是极为必要的,可以有效地提高临床的治疗效果。
Objective:To analyze the clinical value of microcolumn gel immunoassay in detecting the level of antitumor drug antibodies in patients'serum.Methods:From January 2018 to January 2020,serum samples of 80 tumor patients were selected,of which 37 were given trastuzumab antibody,and the remaining 43 were given capecitabine antibody.Analyze the level of anti-tumor drug antibodies in patients'serum.Results:After checking the serum samples of 80 patients,there were antibodies in the sera of 5 patients,with a detection rate of 6.25%.Among them,there were antibodies to trastuzumab in the sera of 1 patient and antibodies to trastuzumab in the sera of 4 patients.The detection rate of capecitabine antibody and trastuzumab antibody was 2.70%,while the detection rate of capecitabine was 9.30%.The detection rate of trastuzumab antibody was lower than that of capecitabine The detection rate.Conclusion:Patients with tumor diseases need to take anti-tumor drugs for a long time.Anti-tumor drug antibodies may appear in the patient's body,which greatly reduces the effect of anti-tumor drugs and causes a variety of immune adverse reactions.Therefore,reduce the patient's body The antibody production rate of anti-tumor drugs is extremely necessary,which can effectively improve the clinical therapeutic effect.
作者
陈笛维
Chen Diwei(Third People's Hospital of Banan District,Chongqing City,Chongqing 401338)
出处
《中国社区医师》
2020年第35期94-95,共2页
Chinese Community Doctors
关键词
微柱凝胶免疫实验
血清
抗肿瘤药物
抗体
临床应用
Microcolumn gel immunoassay
Serum
Anti-tumor drugs
Antibody
Clinical application
